Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

184.51 +1.90 (+1.04%)

Streaming Delayed Price Updated: 1:42 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9

...

57 58 Next >

Nvidia To Rally Around 69%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

June 25, 2025

Via Benzinga

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

June 25, 2025

From Biogen Inc.

Via GlobeNewswire

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? ↗

June 25, 2025

Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.

Via Investor's Business Daily

What Does the Market Think About Biogen? ↗

June 17, 2025

Via Benzinga

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms ↗

June 22, 2025

Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen.

Via Stocktwits

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

June 18, 2025

From Biogen Inc.

Via GlobeNewswire

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics ↗

June 16, 2025

Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash.

Via Stocktwits

Topics Government

Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal ↗

June 16, 2025

Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio.

Via Benzinga

Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million ↗

June 16, 2025

The deal expands Supernus Pharmaceuticals' presence in the nonpsychiatric space.

Via Investor's Business Daily

Topics ETFs

1 Profitable Stock with Exciting Potential and 2 to Avoid

June 13, 2025

A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Via StockStory

Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results ↗

June 12, 2025

UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus standard care.

Via Benzinga

Demystifying Biogen: Insights From 11 Analyst Reviews ↗

June 12, 2025

Via Benzinga

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

June 12, 2025

From Biogen Inc.

Via GlobeNewswire

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 03, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

May 29, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Biogen...

Via StockStory

Topics Artificial Intelligence

Uncover the latest developments among S&P500 stocks in today's session. ↗

May 29, 2025

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.

Via Chartmill

Stay informed with the top movers within the S&P500 index on Thursday. ↗

May 29, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

May 27, 2025

Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development expertise

From Biogen Inc.

Via GlobeNewswire

What's going on in today's session: S&P500 movers ↗

May 19, 2025

Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive...

Via Chartmill

BIIB Q1 Earnings Call: New Product Growth Outpaces Declining MS Franchise Amid Lowered Guidance

May 15, 2025

Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was 1.9% above...

Via StockStory

Topics World Trade

Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards? ↗

May 14, 2025

Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April.

Via Benzinga

Topics Stocks

3 Cash-Producing Stocks Skating on Thin Ice

May 13, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know

May 12, 2025

A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides...

Via StockStory

Topics Government Stocks World Trade

2 Mid-Cap Stocks to Keep an Eye On and 1 to Ignore

May 06, 2025

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...

Via StockStory

4 Stocks to Buy for a Potential “Summer Panic” ↗

May 04, 2025

Luke Lango predicts a major event on May 7 will trigger a flood of cash – as much as $7 trillion – to rush back into U.S. stocks. It’s a catalyst that could change the entire market dynamic and create...

Via InvestorPlace

Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact ↗

May 01, 2025

Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.

Via Benzinga

Biogen (NASDAQ:BIIB) Beats Q1 Sales Targets

May 01, 2025

Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was...

Via StockStory

Topics Artificial Intelligence

Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar ↗

May 01, 2025

The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs.

Via Investor's Business Daily

Topics Earnings

Biogen Earnings: What To Look For From BIIB

April 30, 2025

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.